Across TCGA pan-cancer cohorts, RPSAP59 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of RPSAP59’s most consistent transcriptional readouts.
The strongest signal is observed in prostate adenocarcinoma (PRAD), where RPSAP59 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPSAP59 is over-expressed in tumor.
PRAD are the cancer types where RPSAP59 tumor–normal differential expression is most reproducible.